{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T10:17:50Z","timestamp":1777889870602,"version":"3.51.4"},"reference-count":48,"publisher":"SAGE Publications","issue":"2","license":[{"start":{"date-parts":[[2015,3,1]],"date-time":"2015-03-01T00:00:00Z","timestamp":1425168000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Perit Dial Int"],"published-print":{"date-parts":[[2016,3]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>The use of automated and continuous ambulatory peritoneal dialysis (APD and CAPD) prescriptions (Rxs) to achieve adequate uremic toxin and fluid removal targets is important for attaining optimal patient outcomes. One approach for predicting such Rxs is the use of kinetic modeling.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec sec-type=\"methods\">\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      Demographic data and peritoneal membrane characteristics derived from a peritoneal equilibration test (PET) were available from 1,005 patients in North American centers who participated in a national adequacy initiative in 1999. Twelve patient subgroups were identified according to peritoneal membrane transport type and tertiles of total body water, assumed equal to urea distribution volume (V\n                      <jats:sub>urea<\/jats:sub>\n                      ). Each patient was then modeled using PD Adequest 2.0 to be treated by 12 CAPD and 34 APD Rxs using both glucose and icodextrin solutions to achieve adequacy targets of weekly urea Kt\/V of 1.7 and 1 L of daily ultrafiltration (UF). Residual kidney function (RKF) was assumed to be 0, 2, 4, and 6 mL\/min. Feasible peritoneal dialysis (PD) Rxs were identified where: 1) the 95% confidence limit achieved the goal of meeting the targets for urea Kt\/V, daily UF, and both in 85%, 75%, and 70% of patients, respectively; 2) average PD solution dextrose concentration was &lt; 2.5%; and 3) the number of daytime exchanges was minimized.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec sec-type=\"results\">\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Feasible PD Rxs were similar when RKF was \u2265 2 mL\/min, allowing condensed recommendations based on RKF \u2265 2 mL\/min or &lt; 2 mL\/min. Individuals with lower or slower membrane transport required relatively greater 24-h solution volumes to achieve adequacy targets when RKF fell below 2 mL\/min. With increasing V\n                      <jats:sub>urea<\/jats:sub>\n                      , there was disproportionately greater dependence on RKF to achieve targets. While multiple Rxs achieving urea Kt\/V and daily UF goals were identified for all membrane transport types, use of icodextrin in the long dwell reduced the need for a midday exchange in APD, glucose exposure, required fill and 24-h dwell volumes, irrespective of RKF and V\n                      <jats:sub>urea<\/jats:sub>\n                      . While these benefits were most notable in high and high-average transporters, similar results were also seen in low and low-average transporters.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>\n                      Kinetic modeling identified multiple APD and CAPD Rxs that achieved adequate uremic solute and fluid removal for patients, irrespective of RKF and V\n                      <jats:sub>urea<\/jats:sub>\n                      . Use of icodextrin rather than glucose in the long dwell reduced the complexity of the PD regimen, total glucose exposure, and 24-h total treatment solution volumes. Irrespective of modeling, adequacy of any PD prescription should be based upon individual clinical evaluation both for volume and solute removal.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.3747\/pdi.2014.00255","type":"journal-article","created":{"date-parts":[[2015,8,20]],"date-time":"2015-08-20T22:29:18Z","timestamp":1440109758000},"page":"188-195","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":5,"title":["Volume-Based Peritoneal Dialysis Prescription Guide to Achieve Adequacy Targets"],"prefix":"10.1177","volume":"36","author":[{"given":"Alp","family":"Akonur","sequence":"first","affiliation":[{"name":"Medical Products (Renal), Baxter Healthcare Corporation, Round Lake &amp; Deerfield, Illinois, USA; and University of Oklahoma, Tulsa, Oklahoma, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Catherine A.","family":"Firanek","sequence":"additional","affiliation":[{"name":"Medical Products (Renal), Baxter Healthcare Corporation, Round Lake &amp; Deerfield, Illinois, USA; and University of Oklahoma, Tulsa, Oklahoma, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mary E.","family":"Gellens","sequence":"additional","affiliation":[{"name":"Medical Products (Renal), Baxter Healthcare Corporation, Round Lake &amp; Deerfield, Illinois, USA; and University of Oklahoma, Tulsa, Oklahoma, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Audrey M.","family":"Hutchcraft","sequence":"additional","affiliation":[{"name":"Medical Products (Renal), Baxter Healthcare Corporation, Round Lake &amp; Deerfield, Illinois, USA; and University of Oklahoma, Tulsa, Oklahoma, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pranay","family":"Kathuria","sequence":"additional","affiliation":[{"name":"Medical Products (Renal), Baxter Healthcare Corporation, Round Lake &amp; Deerfield, Illinois, USA; and University of Oklahoma, Tulsa, Oklahoma, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James A.","family":"Sloand","sequence":"additional","affiliation":[{"name":"Medical Products (Renal), Baxter Healthcare Corporation, Round Lake &amp; Deerfield, Illinois, USA; and University of Oklahoma, Tulsa, Oklahoma, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2015,3]]},"reference":[{"key":"e_1_3_3_2_2","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.V72198"},{"key":"e_1_3_3_3_2","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.V1351307"},{"key":"e_1_3_3_4_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1523-1755.2003.00098.x"},{"issue":"9","key":"e_1_3_3_5_2","first-page":"ix24","article-title":"European best practice guidelines for peritoneal dialysis. Adequacy of peritoneal dialysis.","volume":"20","author":"Dombros N.V.","year":"2005","unstructured":"DombrosN.V., DratwaM., FerianiM., GokalR., Heimb\u00fcrgerO., KredietR.T. European best practice guidelines for peritoneal dialysis. Adequacy of peritoneal dialysis. Nephrol Dial Transplant 2005; 20(Suppl 9): ix24\u20137.","journal-title":"Nephrol Dial Transplant"},{"issue":"1","key":"e_1_3_3_6_2","first-page":"S1","article-title":"KDOQI clinical practice guidelines and clinical practice recommendations for 2006 updates: hemodialysis adequacy, peritoneal dialysis adequacy and vascular access.","volume":"48","author":"National Kidney Foundation.","year":"2006","unstructured":"National Kidney Foundation. KDOQI clinical practice guidelines and clinical practice recommendations for 2006 updates: hemodialysis adequacy, peritoneal dialysis adequacy and vascular access. Am J Kidney Dis 2006; 48(Suppl 1): S1\u2013232.","journal-title":"Am J Kidney Dis"},{"key":"e_1_3_3_7_2","doi-asserted-by":"publisher","DOI":"10.1177\/089686080602600502"},{"key":"e_1_3_3_8_2","doi-asserted-by":"crossref","unstructured":"WoodrowG. DavisS. Peritoneal Dialysis in CKD. http:\/\/www.renal.org\/guidelines\/modules\/peritoneal-dialysis-in-ckd#sthash.jaX1OBrk.dpbs 30 July 2010.","DOI":"10.1177\/089686081003001S10"},{"key":"e_1_3_3_9_2","doi-asserted-by":"publisher","DOI":"10.3747\/pdi.2011.00026"},{"key":"e_1_3_3_10_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1523-1755.2001.060002767.x"},{"key":"e_1_3_3_11_2","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfp395"},{"key":"e_1_3_3_12_2","doi-asserted-by":"publisher","DOI":"10.3747\/pdi.2009.00140"},{"key":"e_1_3_3_13_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.ASN.0000092146.67909.E2"},{"key":"e_1_3_3_14_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1523-1755.2005.00512.x"},{"key":"e_1_3_3_15_2","doi-asserted-by":"publisher","DOI":"10.1177\/089686080602600410"},{"key":"e_1_3_3_16_2","doi-asserted-by":"publisher","DOI":"10.1177\/089686080202200406"},{"key":"e_1_3_3_17_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0017148"},{"key":"e_1_3_3_18_2","doi-asserted-by":"publisher","DOI":"10.5301\/ijao.5000080"},{"key":"e_1_3_3_19_2","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gft296"},{"key":"e_1_3_3_20_2","doi-asserted-by":"publisher","DOI":"10.3747\/pdi.2013.00066"},{"key":"e_1_3_3_21_2","doi-asserted-by":"publisher","DOI":"10.3747\/pdi.2013.00057"},{"key":"e_1_3_3_22_2","doi-asserted-by":"publisher","DOI":"10.1159\/000093670"},{"key":"e_1_3_3_23_2","first-page":"99","article-title":"Peritoneal dialysis adequacy: not just small solute clearance.","volume":"24","author":"Yalavarthy R.","year":"2008","unstructured":"YalavarthyR., TeitelbaumI. Peritoneal dialysis adequacy: not just small solute clearance. Adv Perit Dial 2008; 24: 99\u2013103.","journal-title":"Adv Perit Dial"},{"key":"e_1_3_3_24_2","doi-asserted-by":"publisher","DOI":"10.1177\/089686080202200503"},{"key":"e_1_3_3_25_2","doi-asserted-by":"publisher","DOI":"10.1177\/089686080702702s35"},{"key":"e_1_3_3_26_2","doi-asserted-by":"publisher","DOI":"10.1038\/nrneph.2010.68"},{"key":"e_1_3_3_27_2","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.V1251046"},{"key":"e_1_3_3_28_2","doi-asserted-by":"publisher","DOI":"10.1177\/089686088700700306"},{"key":"e_1_3_3_29_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1523-1755.62.s81.4.x"},{"key":"e_1_3_3_30_2","doi-asserted-by":"publisher","DOI":"10.3747\/pdi.2012.00261"},{"key":"e_1_3_3_31_2","article-title":"Icodextrin simplifies PD therapy by equalizing UF and sodium removal among patient transport types during long dwells: a modeling study.","author":"Akonur A.","year":"2014","unstructured":"AkonurA., SloandJ., DavisI., LeypoldtJ. Icodextrin simplifies PD therapy by equalizing UF and sodium removal among patient transport types during long dwells: a modeling study. Perit Dial Int 2014. Epub ahead of print.","journal-title":"Perit Dial Int"},{"key":"e_1_3_3_32_2","doi-asserted-by":"publisher","DOI":"10.1093\/ajcn\/33.1.27"},{"key":"e_1_3_3_33_2","doi-asserted-by":"publisher","DOI":"10.1177\/089686089601600509"},{"key":"e_1_3_3_34_2","doi-asserted-by":"publisher","DOI":"10.1177\/089686089901900611"},{"key":"e_1_3_3_35_2","doi-asserted-by":"publisher","DOI":"10.1177\/089686080602600412"},{"key":"e_1_3_3_36_2","doi-asserted-by":"publisher","DOI":"10.1093\/biomet\/26.4.404"},{"key":"e_1_3_3_37_2","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-0258(19980430)17:8<857::AID-SIM777>3.0.CO;2-E"},{"key":"e_1_3_3_38_2","doi-asserted-by":"publisher","DOI":"10.3747\/pdi.2009.00178"},{"key":"e_1_3_3_39_2","doi-asserted-by":"publisher","DOI":"10.1053\/j.ajkd.2014.07.003"},{"key":"e_1_3_3_40_2","doi-asserted-by":"publisher","DOI":"10.1038\/ki.1991.216"},{"key":"e_1_3_3_41_2","doi-asserted-by":"publisher","DOI":"10.3747\/pdi.2010.00012"},{"key":"e_1_3_3_42_2","doi-asserted-by":"publisher","DOI":"10.1177\/089686081403400401"},{"key":"e_1_3_3_43_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1523-1755.2005.191_2.x"},{"key":"e_1_3_3_44_2","doi-asserted-by":"publisher","DOI":"10.1038\/ki.1995.169"},{"key":"e_1_3_3_45_2","doi-asserted-by":"publisher","DOI":"10.1177\/089686080902900509"},{"key":"e_1_3_3_46_2","doi-asserted-by":"publisher","DOI":"10.3747\/pdi.2011.00175"},{"key":"e_1_3_3_47_2","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfs592"},{"key":"e_1_3_3_48_2","doi-asserted-by":"publisher","DOI":"10.3747\/pdi.2012.00189"},{"key":"e_1_3_3_49_2","doi-asserted-by":"publisher","DOI":"10.1177\/089686080102100514"}],"container-title":["Peritoneal Dialysis International: Journal of the International Society for Peritoneal Dialysis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.3747\/pdi.2014.00255","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.3747\/pdi.2014.00255","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.3747\/pdi.2014.00255","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T05:22:34Z","timestamp":1777612954000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.3747\/pdi.2014.00255"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,3]]},"references-count":48,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2016,3]]}},"alternative-id":["10.3747\/pdi.2014.00255"],"URL":"https:\/\/doi.org\/10.3747\/pdi.2014.00255","relation":{},"ISSN":["0896-8608","1718-4304"],"issn-type":[{"value":"0896-8608","type":"print"},{"value":"1718-4304","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,3]]}}}